Supply of Fluoxetine 20mg capsules by Generic Health Pty

Overview

The Therapeutic Goods Act 1989, enacted to regulate the supply of therapeutic goods in Australia, addresses the need for quality, safety, and efficacy of these goods. In 2012, the Therapeutic Goods Administration, acting under the authority of the Secretary of the Department of Health and Ageing, issued a notice under sections 14 and 14A of the Act to permit the supply of fluoxetine hydrochloride capsules by Generic Health Pty for a limited period. This consent was granted despite the product not fully conforming to the Therapeutic Goods Order No. 69, specifically in regard to the labelling of the active ingredient on the carton. The consent, subject to specific conditions, allows the supply of certain batches of fluoxetine hydrochloride capsules for six months, with a requirement that future batches must comply with the approved labelling standards. This action underscores the regulatory body's commitment to maintaining therapeutic goods standards while allowing flexibility in certain circumstances.

Scope and Application

The Therapeutic Goods Act 1989, as referenced in the 2012 Gazette entry, pertains to the regulation of therapeutic goods in Australia. Specifically, this legislation governs the approval and conditions for the supply of therapeutic goods, including prescription and over-the-counter medicines. The Act applies to entities involved in the supply of these goods, including pharmaceutical companies, wholesalers, and retailers, as well as to the therapeutic goods themselves. The consent issued by the delegate of the Secretary of the Department of Health and Ageing under the Act applies nationally, extending its reach across all states and territories within the Commonwealth of Australia. This consent is limited in its scope to the specific product fluoxetine (as hydrochloride) (AUSCAP ASPEN) 20 mg capsules, produced by Generic Health Pty, and specifically to the batches B200E2004 and B200E2005, which have a discrepancy in the naming of the active ingredient on the carton labels. The consent granted is conditional and time-bound, lasting for six months, during which the specified batches can be supplied under the conditions outlined. This consent does not affect other batches or products, and all future batches must adhere to the approved version of the active ingredient naming as stipulated by TGO 69.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) provides a framework for regulating therapeutic goods in Australia, including medicines, medical devices, and blood and blood components. Under sections 14 and 14A of the Act, the delegate of the Secretary of the Department of Health and Ageing can consent to certain activities or products that might otherwise not comply with the regulations, provided specific conditions are met. In this case, the delegate has consented to the supply of fluoxetine (as hydrochloride) (AUSCAP ASPEN) 20 mg capsules by Generic Health Pty, despite the product not fully conforming with paragraph 4 of the Therapeutic Goods Order (TGO) 69. This consent is given on the condition that the product's carton labels must express the active ingredient as 'Fluoxetine (as hydrochloride) capsules' for all future batches to comply with TGO 69 and TGA-approved artwork. The obligations imposed on the parties governed by the Act include ensuring that all therapeutic goods meet the necessary standards for safety, quality, and efficacy as prescribed by the Therapeutic Goods Order. Generic Health Pty, in this context, must adhere to the conditions set forth in the consent. Specifically, the company must ensure that all future batches of the fluoxetine (as hydrochloride) (AUSCAP ASPEN) 20 mg capsules are packed with carton labels that correctly state the active ingredient as 'Fluoxetine (as hydrochloride)'. This requirement is crucial to maintain compliance with TGO 69 and ensure the product meets the regulatory standards set by the Therapeutic Goods Administration (TGA). Failure to comply with the conditions of the consent, or more broadly, any failure to adhere to the provisions of the Therapeutic Goods Act or the Therapeutic Goods Orders, may result in various penalties. The Act allows for both civil and criminal consequences for breaches, depending on the severity and intent of the non-compliance. Civil penalties can include fines, while criminal penalties can include imprisonment. For example, section 35 of the Act imposes a maximum penalty of $220,000 for individuals and $1,100,000 for bodies corporate for each offence of supplying a prohibited therapeutic good. Additionally, section 35A of the Act imposes a maximum penalty of $220,000 for individuals and $1,100,000 for bodies corporate for offences related to false or misleading representations about therapeutic goods. Generic Health Pty must, therefore, ensure strict compliance to avoid these potential consequences.